A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples